<DOC>
	<DOC>NCT00359229</DOC>
	<brief_summary>Primary objective: 1. To evaluate the efficacy of Zolpidem 5mg for 1 week in elderly patients with insomnia in China Secondary objectives: 1. To evaluate the safety of Zolpidem 5mg for 3 weeks in elderly patients with insomnia in China. 2. To evaluate the efficacy of Zolpidem 5mg for 3 weeks in elderly patients with insomnia in China</brief_summary>
	<brief_title>Stilnox Treatment in Elderly Patients With Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Primary outpatient insomniac patient defined by DSMIV criteria Insomnia history lasted at least 3 months , this history must include a selfreported usual sleep latency of 30 minutes or more and either 3 or more awakenings per night on average or a usual total sleep time of â‰¤6.5 hours Usage of hypnotics within the previous 13 weeks before inclusion depending on the halflife of the hypnotics that would affect the study effect Concomitant usage of other hypnotics (benzodiazepines and Nonbenzodiazepines) during the course if the study. Concomitant usage of the following Central Nervous System active medicine : antipsychotics , antidepressants ,anxiolytics, lithium and other psychotropic drugs. The score of Hamilton Depression Rating Scale (HAMD24 ) more than 17. The score of Hamilton Anxiety Rating Scale (HAMA14 ) more than 14. Patients having known hypersensitivity to Stilnox or any of the ingredients in the products Patient with severe respiratory insufficiency Patients suffering from sleep apnoea syndrome Patients with known severe hepatic (risk of encephalopathy) and /or renal insufficiency, or other severe organ diseases Patients suffering from severe myasthenia gravis Patients with the previous history of drug abuse, drug dependence and drug addiction Any other disease state or major psychiatric condition that might affect study result The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>